
|Videos|May 24, 2017
A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid Tumors
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Dr Hans Lee on the Game-Changing Myeloma Research From ASH 2025
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
The Targeted Pulse: Blood and Breast Cancer News
5









































